期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 28, 期 29, 页码 4521-4530出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2010.29.7929
关键词
-
类别
资金
- Celgene
- Cephalon
- Millennium Pharmaceuticals
- Onyx Pharmaceuticals
- Facet Biotech
Purpose To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group. Patients and Methods In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized. Results Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation. Conclusion New strategies are necessary to make Allo-SCT safer and more effective for patients with MM. Until this is achieved, Allo-RIC in myeloma should only be recommended in the context of clinical trials. J Clin Oncol 28:4521-4530. (C) 2010 by American Society of Clinical Oncology
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据